Anwesha Dey

Anwesha Dey is a Distinguished Scientist and Executive Director of AI-oncology and cancer biology and in the Research Oncology Department at Genentech. Her scientific research at Genentech is focused on understanding the biology of Hippo and PI3K signaling pathways and how they can be targeted for cancer therapy. Anwesha was part of the team whose research led to the most recent approval of Itovebi, which targets PIK3CA using the PI3K pathway. She has served as both the Project Team Leader and Biology lead for drug discovery programs at Genentech where she leads an interdisciplinary team focused on biology, drug discovery and translation to make medicines for cancer. She currently serves on the Scientific Advisory Board (SAB) of the Keystone Symposia. Anwesha is a recipient of the 2022 GWP Emerging Leader Award at Genentech, the 2023 UMBC Alumni Award for Distinguished service, the 2023 Genentech Changemaker award and is one of the 2024 National Academy of Medicine’s emerging leader in health and medicine scholar.